The use of fecal calprotectin (fCAL) in clinical routine is demonstrated beyond doubt. We now have extensive knowledge of its efficacy for IBD/IBS differentiation and IBD monitoring, as it has been shown to be an excellent surrogate biomarker for inflammatory status of the gut that correlates well with endoscopic activities.

In 2015, IBDoc^® the first home test kit for fCAL obtained the CE marking and took monitoring of IBD patients to a new level. IBDoc^® was proven to be as efficient as a lab test and very well accepted by patients. In addition to avoid unnecessary procedures, home testing can avoid hospital visits altogether for the patients. This not only saves time for both, the patients and the healthcare professionals, but also reduces costs. As technology continues to improve, patients are now monitored from afar in virtual clinics until they need a physical appointment.

Learn more about IBDoc^® in our Webinar, taking place on Wednesday 27th May 2020 from 2 -4 PM (CEST). In this webinar we will present the newest product updates, available material and success stories.

You will receive detailed informations about the webinar once it is getting closer.